OSI Pharmaceuticals, Inc. Announces Fourth Quarter and 2009 Full Year Tarceva Sales at JP Morgan Healthcare Conference
13 January 2010 - 1:00AM
Business Wire
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) will present fourth
quarter and year end Tarceva® (erlotinib) sales today during the
Company’s presentation at the 28th Annual JP Morgan Healthcare
Conference in San Francisco, CA. For the three months ended
December 31, 2009, Tarceva U.S. net sales, as communicated to the
Company by its collaborator Roche, were approximately $137 million.
U.S. sales increased approximately $20 million (or 17%) over the
same period last year and were up approximately $19 million over
third quarter sales of approximately $118 million. Fourth quarter
net sales outside the U.S. were approximately $196 million, also
representing a 17% increase over the same period last year and
an increase of approximately $13 million over third quarter
sales.
Total worldwide net sales of Tarceva for 2009, were
approximately $1.2 billion, representing a 7% growth in global
sales compared to 2008. Full year net sales of Tarceva in the U.S.
totaled approximately $479 million with full year net sales outside
of the U.S. totaling approximately $724 million. The Company
expects to present full fourth quarter and year end financial
results in its year end earnings call.
About OSI
Pharmaceuticals
OSI Pharmaceuticals is committed to "shaping medicine and
changing lives" by discovering, developing and commercializing
high-quality, novel and differentiated targeted medicines designed
to extend life and improve the quality of life for patients with
cancer and diabetes/obesity. For additional information about OSI,
please visit http://www.osip.com.
This news release contains forward-looking statements. These
statements are subject to known and unknown risks and uncertainties
that may cause actual future experience and results to differ
materially from the statements made. Factors that might cause such
a difference include, among others, OSI's and its collaborators'
abilities to effectively market and sell Tarceva and to expand the
approved indications for Tarceva, OSI’s ability to protect its
intellectual property rights, safety concerns regarding Tarceva,
competition to Tarceva and OSI’s drug candidates from other
biotechnology and pharmaceutical companies, the completion of
clinical trials, the effects of FDA and other governmental
regulation, including pricing controls, OSI's ability to
successfully develop and commercialize drug candidates, and other
factors described in OSI Pharmaceuticals' filings with the
Securities and Exchange Commission.
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Osi Pharmaceuticals Inc. (MM) (NASDAQ): 0 recent articles
More OSI Pharmaceuticals, Inc. News Articles